Osel Overview
- Founded
- 1996
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Grant
- Latest Deal Amount
- $3.48M
- Investors
- 1
Osel General Information
Description
Developer of live biotherapeutic products intended to harness the microbiome to improve health. The company's products address major gastrointestinal, infectious diseases and women's health indications as well as treat abnormal conditions resulting from a disruption of the human microbiome, enabling healthcare providers to find a cure for their patients.
Contact Information
Website
www.oselinc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 320 Logue Avenue
- Mountain View, CA 94043
- United States
+1 (650) 000-0000
Osel Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 01-Jan-2016 | $3.48M | 00.000 | Completed | Generating Revenue | |
| 6. Grant | 01-Jan-2005 | 00000 | 00.000 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series C) | 21-Dec-2004 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 4. Grant | 01-Jan-2003 | 00000 | Completed | Generating Revenue | ||
| 3. Grant | 01-Jan-2002 | 00.000 | Completed | Generating Revenue | ||
| 2. Grant | 01-Jan-2001 | $140K | Completed | Generating Revenue | ||
| 1. Grant | 01-Jan-1999 | $129K | Completed | Generating Revenue |
Osel Patents
Osel Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3843701-A2 | Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health | Pending | 30-Aug-2018 | 0000000000 | |
| US-20210275628-A1 | Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health | Pending | 30-Aug-2018 | 0000000000 | |
| US-20200164007-A1 | Use of vaginal lactobacilli for improving the success rate of in vitro fertilization | Pending | 07-Jul-2017 | 00000000 | |
| CA-3068974-A1 | Use of vaginal lactobacilli for improving the success rate of in vitro fertilization | Pending | 07-Jul-2017 | 00000000 | |
| AU-2018298116-A1 | Use of vaginal lactobacilli for improving the success rate of in vitro fertilization | Pending | 07-Jul-2017 | C12N1/20 |
Osel Executive Team (6)
Osel Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Michael Cannon | Self | Board Member | 000 0000 |
| Peter Lee MD | Osel | Co-Founder, Chief Executive Officer & Executive Chairman | 000 0000 |
| Robert Lee | Self | Board Member | 000 0000 |
| Sandy Chau | Self | Board Member | 000 0000 |
Osel Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOsel Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |